WhatsApp Group Join Now
WhatsApp Channel Join Now
Telegram Group Join Now
HomeAurobindo Pharma LtdAurobindo Pharma walk-in interviews on 2nd June 2024

Aurobindo Pharma walk-in interviews on 2nd June 2024

AUROBINDO PHARMA LTD, also known as APL Healthcare Ltd, is an expanding Indian multinational pharmaceutical manufacturing company that achieved revenues exceeding US$2.8 Billion in 2018-19. The company has a strong presence in over 34 countries and exports its products to 155 nations. APL holds the position of the 2nd Largest Generic Company in terms of Rx dispensed in the USA. Additionally, APL is recognized as one of the Top 10 Generic players in various European countries including France, Germany, Portugal, UK, Italy, Czech Republic, Netherlands, and Belgium.

Greetings from Aurobindo Pharma Ltd!

We are conducting walk-in interview for Regulatory Affairs department on 2nd June 2024 @ Hyderabad.

Regulatory Affairs US/Europe Market

Experience: 2 – 6 yrs of relevant experience

Qualification: M Pharma

Job Description :

For US Market:

  • Preparation, review and compilation of assigned ANDAs Topical/Dermatological Formulations.Projects for filing and knowledge of eCTD, Module 2 and 3. Hands on experience in reviewing CMC documents of Solid and Liquid Oral Dosage forms.

For Europe Market:

  • Competent with Europe filing wrt. Module 2&3. well versed with EU – Regulatory guidance and processes. Post Approval Variations and Compilations.

Work Location: Hyderabad

Walk-in interview details

Date & Time: 2nd June , 9.00 AM – 2.00 PM
Venue: APL Research Center I Sy.No.313&314, Bachupalli, Hyderabad, Telangana – 500090
Contact – Sravan Kumar Bhimuni

5/5 (1 Review)

Discover more from Pharma Walks

Subscribe to get the latest posts sent to your email.

RELATED JOBS

Join us

3,654FansLike
5,353FollowersFollow
4,233FollowersFollow
9,843SubscribersSubscribe

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Discover more from Pharma Walks

Subscribe now to keep reading and get access to the full archive.

Continue reading